Suzumura A, Sawada M
Department of Neurology, Nara Medical University, Kashihara, Japan.
Life Sci. 1999;64(14):1197-203. doi: 10.1016/s0024-3205(99)00051-x.
Tumor necrosis factor alpha (TNF alpha) is considered to play a critical role in the development of various pathological processes in the central nervous system (CNS), such as neuronal degeneration, demyelination and gliosis. In order to search for agents which suppress TNF alpha production in the CNS for future treatment of these pathological conditions, the effects of a synthetic oral inotropic agent, vesnarinone, on murine microglia were examined. Vesnarinone significantly suppressed TNF alpha production by microglia in a dose-dependent manner, without affecting their viability, enzyme activity or expression of the major histocompatibility complex. Since the reported maximum serum concentration is high enough to suppress TNF alpha production in vitro (about 20 microM) after oral administration of the therapeutic dose of vesnarinone, this drug will be useful to treat intractable neurological diseases such as neurodegenerative disorders, multiple sclerosis or HIV-related neurological disorders.
肿瘤坏死因子α(TNFα)被认为在中枢神经系统(CNS)各种病理过程的发展中起关键作用,如神经元变性、脱髓鞘和胶质增生。为了寻找能抑制CNS中TNFα产生的药物以用于未来对这些病理状况的治疗,研究了一种合成的口服强心剂维司力农对小鼠小胶质细胞的作用。维司力农以剂量依赖的方式显著抑制小胶质细胞产生TNFα,而不影响其活力、酶活性或主要组织相容性复合体的表达。由于报道的口服治疗剂量的维司力农后最大血清浓度足够高,足以在体外抑制TNFα的产生(约20微摩尔),这种药物将有助于治疗难治性神经疾病,如神经退行性疾病、多发性硬化症或与HIV相关的神经疾病。